Review
doi: 10.1038/nrc.2017.8.
Epub 2017 Mar 17.
Advances and challenges in targeting FGFR signalling in cancer
Affiliations
- PMID: 28303906
- DOI: 10.1038/nrc.2017.8
Item in Clipboard
Review
Advances and challenges in targeting FGFR signalling in cancer
Nat Rev Cancer.
2017 May.
Abstract
Fibroblast growth factors (FGFs) and their receptors (FGFRs) regulate numerous cellular processes. Deregulation of FGFR signalling is observed in a subset of many cancers, making activated FGFRs a highly promising potential therapeutic target supported by multiple preclinical studies. However, early-phase clinical trials have produced mixed results with FGFR-targeted cancer therapies, revealing substantial complexity to targeting aberrant FGFR signalling. In this Review, we discuss the increasing understanding of the differences between diverse mechanisms of oncogenic activation of FGFR, and the factors that determine response and resistance to FGFR targeting.
Similar articles
-
Targeting FGFR Signaling in Cancer.Clin Cancer Res. 2015 Jun 15;21(12):2684-94. doi: 10.1158/1078-0432.CCR-14-2329. Clin Cancer Res. 2015. PMID: 26078430 Review.
-
Recent developments and advances of FGFR as a potential target in cancer.Future Med Chem. 2018 Sep 1;10(17):2109-2126. doi: 10.4155/fmc-2018-0103. Epub 2018 Aug 1. Future Med Chem. 2018. PMID: 30066580 Review.
-
Implications of Fibroblast Growth Factors (FGFs) in Cancer: From Prognostic to Therapeutic Applications.Curr Drug Targets. 2019;20(8):852-870. doi: 10.2174/1389450120666190112145409. Curr Drug Targets. 2019. PMID: 30648505 Review.
-
Targeting the fibroblast growth factor receptor family in cancer.Cancer Treat Rev. 2016 May;46:51-62. doi: 10.1016/j.ctrv.2016.03.015. Epub 2016 Apr 12. Cancer Treat Rev. 2016. PMID: 27109926 Review.
-
De-regulated FGF receptors as therapeutic targets in cancer.Pharmacol Ther. 2010 Jan;125(1):105-17. doi: 10.1016/j.pharmthera.2009.10.001. Epub 2009 Oct 27. Pharmacol Ther. 2010. PMID: 19874848 Review.
Cited by
-
Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas.Int J Mol Sci. 2022 Nov 9;23(22):13784. doi: 10.3390/ijms232213784. Int J Mol Sci. 2022. PMID: 36430263 Free PMC article. Review.
-
Evolving therapeutic landscape of advanced hepatocellular carcinoma.Nat Rev Gastroenterol Hepatol. 2023 Apr;20(4):203-222. doi: 10.1038/s41575-022-00704-9. Epub 2022 Nov 11. Nat Rev Gastroenterol Hepatol. 2023. PMID: 36369487 Review.
-
Targeting the FGF/FGFR axis and its co-alteration allies.ESMO Open. 2022 Dec;7(6):100647. doi: 10.1016/j.esmoop.2022.100647. Epub 2022 Nov 29. ESMO Open. 2022. PMID: 36455506 Free PMC article.
-
Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study.Cancer Med. 2023 Feb;12(4):4137-4146. doi: 10.1002/cam4.5273. Epub 2022 Sep 20. Cancer Med. 2023. PMID: 36127767 Free PMC article. Clinical Trial.
-
Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2.Proc Natl Acad Sci U S A. 2024 Feb 6;121(6):e2317756121. doi: 10.1073/pnas.2317756121. Epub 2024 Feb 1. Proc Natl Acad Sci U S A. 2024. PMID: 38300868 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
